A Phase II Study of Apatinib in STS Patients

Inclusion Criteria:

* Signed informed consent.
* Histologically proven advanced soft tissue sarcoma, At least one measurable lesion. Including: Synovial sarcoma, leiomyosarcoma, Alveolar soft part sarcoma, Undifferentiated pleomorphic sarcoma / malignant fibrous histiocytoma, Liposarcoma, Fibrosarcoma, Clear cell sarcoma, Epithelioid sarcoma, Angiosarcoma, Spindle cell sarcoma, rhabdomyosarcoma treated by chemotherapy, Ewing's sarcoma of soft tissue/Primitive neuroectodermal tumor. Excluding: Malignant peripheral nerve sheath tumor, chondrosarcoma, Dermatofibrosarcoma protuberans, Gastrointestinal stromal tumor, Inflammatory myofibroblastic sarcoma, Malignant mesothelioma.
* Must have evidence of unresectable residual disease.
* In the last 6 months, at least one chemotherapy regimen (including anthracyclines) was used in patients who failed or were unable to tolerate treatment.
* ECOG ps≤2.
* Life expectancy: more than 3 months.
* Prior aptinib less than 2 weeks and at least 1 month since prior aptinib；at least 1 month since prior inhibitor of mTOR or EGFR pathway.
* Not pregnant or nursing；Fertile patients must use effective contraception.
* Hematopoietic

  * HB≥90g/L
  * Absolute neutrophil count ≥ 1,500/mm\^3
  * Platelet count ≥ 80,000/mm\^3

Exclusion Criteria:

* Uncontrollable hypertension;
* Has influence of oral drugs;
* Patients with high risk of gastrointestinal blooding;
* INR\>1.5×ULN，APTT\>1.5×ULN;
* Allergic to any ingredient of this product;
* Less than 1 month since last major surgery;
* Brain metastases;
* With the second cancer.